title: BRAFV600mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study.
abstract: BACKGROUND
  Mutations in theBRAFgene have been implicated in several human cancers. The objective of this screening study was to identify patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma harboring activatingBRAFV600mutations for enrollment in a vemurafenib clinical study.
  
  
  METHODS
  Formalin-fixed, paraffin-embedded tumor samples were collected and sent to a central laboratory to identify activatingBRAFV600mutations by bidirectional direct Sanger sequencing.
  
  
  RESULTS
  Overall incidence ofBRAFV600Emutation in evaluable patients (n=548) was 3% (95% confidence interval [CI], 1.7-4.7): 11% in colorectal tumors (n=75), 6% in biliary tract tumors (n=16), 3% in non-small cell lung cancers (n=71), 2% in other types of solid tumors (n=180), and 3% in multiple myeloma (n=31). There were noBRAFV600mutations in this cohort of patients with ovarian tumors (n=68), breast cancer (n=86), or prostate cancer (n=21).
  
  
  CONCLUSIONS
  This multicenter, national screening study confirms previously reported incidences ofBRAFV600mutations from single-center studies. Patients identified withBRAFV600mutations were potentially eligible for enrollment in the VE-BASKET study.
authors.affiliation: Medical Research, Rocky Mountain Cancer Centers, Denver, CO.
authors.forename: Allen L
authors.initials: AL
authors.lastname: Cohn
authors.affiliation: US Medical Affairs.
authors.forename: Bann-Mo
authors.initials: BM
authors.lastname: Day
authors.affiliation: Global Safety and Risk Management.
authors.forename: Sarang
authors.initials: S
authors.lastname: Abhyankar
authors.affiliation: US Medical Affairs.
authors.forename: Edward
authors.initials: E
authors.lastname: McKenna
authors.affiliation: Product Development Oncology, Genentech, Inc., South San Francisco, CA.
authors.forename: Todd
authors.initials: T
authors.lastname: Riehl
authors.affiliation: Melanoma Section, Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Puzanov
keywords: PLX4032; genetic testing; proto-oncogene proteins B-raf